Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 OutlookGlobeNewsWire • 02/29/24
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker DiscoveryGlobeNewsWire • 02/06/24
Here's Why Seer, Inc. (SEER) Could be Great Choice for a Bottom FisherZacks Investment Research • 02/02/24
Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024GlobeNewsWire • 02/01/24
Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services ForumGlobeNewsWire • 11/10/23
Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500GlobeNewsWire • 11/08/23
Seer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access CenterGlobeNewsWire • 06/07/23
Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their StudiesGlobeNewsWire • 06/01/23